HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jianfeng Xu Selected Research

familial Prostate cancer

12/2012Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer.
1/2012Germline mutations in HOXB13 and prostate-cancer risk.
7/2011Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility.
9/2005Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease.
5/2004Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer.
1/2003Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.
11/2002Sequence variants in the human 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jianfeng Xu Research Topics

Disease

127Prostatic Neoplasms (Prostate Cancer)
01/2022 - 02/2002
99Neoplasms (Cancer)
05/2022 - 07/2002
12Inflammation (Inflammations)
06/2017 - 01/2002
10Hepatocellular Carcinoma (Hepatoma)
01/2022 - 01/2013
9Neoplasm Metastasis (Metastasis)
01/2021 - 09/2005
9Carcinogenesis
01/2020 - 10/2002
8Infections
06/2021 - 04/2004
7Insulin Resistance
04/2013 - 04/2005
7familial Prostate cancer
12/2012 - 11/2002
6Hemorrhage
01/2021 - 03/2014
6Fibrosis (Cirrhosis)
06/2019 - 03/2014
6Asthma (Bronchial Asthma)
08/2017 - 01/2002
5Genetic Risk Score
01/2022 - 01/2015
5Stomach Neoplasms (Stomach Cancer)
11/2021 - 02/2016
5Disease Progression
10/2020 - 09/2007
5Urinary Bladder Neoplasms (Bladder Cancer)
01/2020 - 12/2014
4Genetic Predisposition to Disease (Genetic Predisposition)
07/2021 - 01/2003
4Hypertrophy
03/2018 - 01/2014
4Breast Neoplasms (Breast Cancer)
11/2016 - 11/2003
4Obesity
07/2016 - 06/2006
3Pain (Aches)
01/2022 - 12/2013
3Colorectal Neoplasms (Colorectal Cancer)
11/2021 - 01/2014
3Venous Thromboembolism
01/2021 - 01/2020
3Ischemia
11/2018 - 12/2002
3Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
12/2017 - 11/2003
3Stroke (Strokes)
07/2016 - 09/2005
3Liver Neoplasms (Liver Cancer)
02/2016 - 07/2003
3Renal Cell Carcinoma (Grawitz Tumor)
01/2016 - 01/2014
3Cardiomegaly (Heart Hypertrophy)
08/2015 - 03/2014
2Sickle Cell Trait
01/2022 - 06/2021
2Esophageal Squamous Cell Carcinoma
11/2021 - 07/2019
2Adenocarcinoma
11/2021 - 01/2021
2Leukemia
01/2021 - 04/2013
2Bronchiectasis
01/2021 - 01/2019
2Sepsis (Septicemia)
03/2020 - 09/2018
2Overweight
01/2020 - 06/2006
2Chronic Hepatitis B
01/2020 - 04/2016
2Pancreatic Neoplasms (Pancreatic Cancer)
01/2020 - 07/2007
2Hepatitis B
01/2020 - 04/2014
2Type 2 Diabetes Mellitus (MODY)
01/2020 - 09/2008
2Hematuria
01/2020 - 01/2019
2Hypospadias
12/2019 - 01/2018

Drug/Important Bio-Agent (IBA)

32DNA (Deoxyribonucleic Acid)IBA
01/2021 - 03/2002
24Genetic Markers (Genetic Marker)IBA
01/2018 - 10/2007
23Prostate-Specific Antigen (Semenogelase)IBA
01/2022 - 07/2002
21Biomarkers (Surrogate Marker)IBA
01/2022 - 02/2009
18Proteins (Proteins, Gene)FDA Link
05/2022 - 02/2005
15Androgen Receptors (Androgen Receptor)IBA
01/2022 - 02/2002
14Biological ProductsIBA
01/2021 - 04/2004
11Messenger RNA (mRNA)IBA
01/2022 - 08/2002
9Dutasteride (Avodart)FDA Link
12/2019 - 01/2012
9AndrogensIBA
12/2012 - 07/2002
7MicroRNAs (MicroRNA)IBA
07/2019 - 05/2010
6Therapeutic UsesIBA
03/2020 - 07/2007
6Interleukin-6 (Interleukin 6)IBA
09/2018 - 10/2004
6EnzymesIBA
01/2017 - 11/2002
6Glucose (Dextrose)FDA LinkGeneric
01/2015 - 11/2011
6Toll-Like Receptors (Toll-Like Receptor)IBA
03/2010 - 04/2004
5Insulin (Novolin)FDA Link
07/2016 - 05/2012
5Scavenger Receptors (Scavenger Receptor)IBA
12/2007 - 10/2002
4Long Noncoding RNAIBA
01/2021 - 11/2011
4Hepatitis B Surface Antigens (HBsAg)FDA Link
01/2020 - 07/2016
4AntigensIBA
01/2020 - 06/2007
4Interleukin-8 (Interleukin 8)IBA
03/2018 - 09/2015
4Small Interfering RNA (siRNA)IBA
01/2018 - 05/2012
4Interleukin-4 (Interleukin 4)IBA
06/2017 - 09/2011
4Interleukin-10 (Interleukin 10)IBA
06/2017 - 10/2012
4Estrogens (Estrogen)FDA Link
01/2014 - 03/2002
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2013 - 09/2006
3Pharmaceutical PreparationsIBA
01/2022 - 04/2013
3hydrogen sulfite (bisulfite)IBA
11/2021 - 02/2009
3RivaroxabanIBA
01/2021 - 01/2020
3CarcinogensIBA
10/2020 - 04/2007
3Hepatitis B e AntigensIBA
01/2020 - 04/2016
3CytokinesIBA
09/2018 - 01/2014
3NucleotidesIBA
01/2018 - 07/2003
3Interleukin-2 (IL2)IBA
06/2017 - 09/2015
3Interleukin-12 (IL 12)IBA
06/2017 - 09/2015
3RNA (Ribonucleic Acid)IBA
07/2016 - 04/2013
3HLA-DQ Antigens (HLA-DQ)IBA
11/2015 - 01/2013
3AntioxidantsIBA
12/2012 - 12/2002
3P-2 (P 2)IBA
01/2012 - 08/2009
3Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA
09/2007 - 11/2003
3Fatty Acids (Saturated Fatty Acids)IBA
01/2007 - 11/2002
3Immunoglobulin E (IgE)IBA
11/2002 - 01/2002
2RadiopharmaceuticalsIBA
05/2022 - 01/2020
2Cell-Free Nucleic AcidsIBA
01/2022 - 11/2021
2alpha-Fetoproteins (alpha-Fetoprotein)IBA
01/2022 - 07/2016
2Hemoglobins (Hemoglobin)IBA
01/2022 - 06/2021
2Enoxaparin (Lovenox)FDA LinkGeneric
01/2021 - 03/2020
2LipopolysaccharidesIBA
03/2020 - 04/2004
2GSK-2838232IBA
01/2020 - 01/2018

Therapy/Procedure

12Therapeutics
01/2022 - 05/2010
5Aftercare (After-Treatment)
01/2020 - 09/2005
4Precision Medicine
05/2022 - 07/2013
4Prostatectomy (Retropubic Prostatectomy)
10/2020 - 09/2008
4Nephrectomy
01/2016 - 03/2014
3Chemoprevention
12/2019 - 03/2011
3Lasers (Laser)
02/2013 - 09/2006
2Castration
01/2021 - 09/2016